Red Team Associates is pleased to announce that Eric M. Nelson, Ph.D., joined Red Team in March 2020 as Managing Director. Eric brings significant drug and medical device product strategic planning experience to Red Team, and has a huge network of large pharma and strategic investment funding alliance partners that he has worked with. He is located in Chapel Hill, North Carolina. At Red Team, Eric will help plan and implement product R&D and commercialization strategic consulting projects for client companies.
Eric is a senior-level experienced professional with backgrounds in biotechnology company business development, R&D strategic due diligence, and pharma partnering. He has helped build several biotech companies from seed-stage to successful M&A/IPO exits. Eric has helped management teams develop products from preclinical late-stage clinical trials in the CNS, rare disease, ophthalmology, oncology, and inflammatory disease areas.
Prior to joining Red Team, Eric held business development positions at Tetra Discovery, a CNS drug discovery company that was acquired by Shionogi, three NIH Institutes and affiliates, NCATS, NINDS, and the Biomarker Consortium, Parent Project Muscular Dystrophy, Tranzyme, acquired by Mallinckrodt and the CROs, Advinus and Cato Research.
Eric’s last corporate positions were as Vice President of Global Business Development at Wyeth Pharmaceuticals/Pfizer, Director of Business Development at Becton Dickinson, and Manager of Business Development at Athena Neurosciences/Elan Pharmaceuticals. He was also Head Biotechnology Stock Analyst at the investment bank, Cowen & Co.
Dr. Nelson started his career in biomedical research with a Ph.D. in molecular pharmacology from The Johns Hopkins School of Medicine, and as a Post-Doctoral Fellow at Harvard University, Department of Biochemistry.
Managing partner, Harris Kaplan, participated in Pharma intelligence‘s 24-hour web event on COVID-19: Lessons Learned and a Path Forward back in July. Session moderator, Melanie Senior, has written a piece for Informa, Virtual Health Care: Where Does This Leave Pharma Marketing?, recounting many of the learnings from Harris’ session, How COVID-19 is Changing Healthcare Delivery. Take a look and let us know how you think the pandemic has affected pharma marketing.
We are pleased to announce that Harris Kaplan, Managing Partner, will be participating in a new 24-hour web event, hosted by Informa, a leading international events, intelligence and scholarly research group. I will be joined by other experts and key opinion leaders from across Biopharma, MedTech, and healthcare as we discuss the impacts of the COVID-19 pandemic and what has been learned so far.
For 24 hours, subject-matter experts will give you an exclusive view into how our industries have responded and adapted to COVID-19 across a series of webinars and virtual events.
Join us and you’ll:
You can register HERE. Once registered, you will be able to particpate live, plus you will be able to listen to all sessions on demand after the live event has closed.
Hope to see you there,
Our very own Lori Thompson is guest blogging this week over at MedTech Strategist. The topic: thinking about your regulatory strategy as a key part of your overall commercial strategy. Please check it out and tell us your thoughts on taking the 510(k) vs PMA pathway.
We have partnered with Ben Franklin’s PRIMA to showcase our unique capabilities plus our new algorithm, RAMP. Please join us for this free virtual workshop on May 21st from 12-1 pm EDT.
Harris Kaplan, managing partner, has partnered with Fred Dotzler to write the cover story for InVivo January 2019. The article delves into what payers are doing in today’s world to try to control the cost of new products, and what steps they plan on taking to better control rising costs in the future.
RTA Joins the Greater Philadelphia Regional Integrated Medicine Alliance (PRIMA) as a Founding Member
Red Team has partnered with Ben Franklin and other area biotech/pharma technology companies to create PRIMA.
“PRIMA links discovery, infrastructure, information and analysis systems and commercialization resources to enable startups, large companies, universities, hospitals, and other nonprofit organizations and regional life science stakeholders to collaborate to accelerate technology innovation and reduce barriers to commercialization.”
Please click below to see the presentation given by Harris Kaplan
Harris to speak at Global Orphan Disease Conference April 2016 on Preparing for The Zero Moment of Truth in Rare Disease Drug Development. Click on the article below to find out more about the The Zero Moment of Truth.
Harris Kaplan, managing partner at Red Team Associates, held a workshop at Life Science Alley on April 7th, 2015.